• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.2,4-二氨基-6-[2-(膦酰甲氧基)乙氧基]嘧啶对多药耐药乙型肝炎病毒突变体的体外活性
Antimicrob Agents Chemother. 2007 Jun;51(6):2240-3. doi: 10.1128/AAC.01440-06. Epub 2007 Mar 19.
2
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.拉米夫定耐药乙型肝炎病毒对阿德福韦和替诺福韦的体外敏感性
Antivir Ther. 2004 Jun;9(3):353-63.
3
6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity.6-[（2-膦酰甲氧基）烷氧基]-2,4-二氨基嘧啶：一类具有抗病毒活性的新型非环状嘧啶核苷膦酸酯。
Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1321-7. doi: 10.1081/NCN-200027573.
4
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.阿德福韦相关的乙型肝炎病毒聚合酶突变对其他抗病毒药物的体外敏感性。
Antivir Ther. 2007;12(3):355-62.
5
Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.一名慢性乙型肝炎患者体内对拉米夫定、阿德福韦酯和恩替卡韦具有多重耐药性的乙肝病毒株的演变与抑制
Antivir Ther. 2010;15(8):1185-90. doi: 10.3851/IMP1679.
6
The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.乙肝病毒的rtA181S突变主要赋予对阿德福韦酯的耐药性。
J Viral Hepat. 2015 Mar;22(3):328-34. doi: 10.1111/jvh.12298. Epub 2014 Aug 14.
7
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.一株对拉米夫定和阿德福韦均具有耐药性突变的人乙肝病毒株对抗病毒药物的敏感性
Hepatology. 2005 Jun;41(6):1391-8. doi: 10.1002/hep.20723.
8
Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.从一位多药耐药的慢性乙型肝炎感染患者中分离出的新型恩替卡韦突变模式的分子特征。
J Clin Virol. 2012 Feb;53(2):130-4. doi: 10.1016/j.jcv.2011.10.011. Epub 2011 Nov 9.
9
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.2',3'-二脱氧-3'-氟鸟苷抗乙型肝炎病毒活性及交叉耐药谱的体外特性研究
Antimicrob Agents Chemother. 2006 Mar;50(3):955-61. doi: 10.1128/AAC.50.3.955-961.2006.
10
Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.乙肝 e 抗原抑制突变增强了阿德福韦耐药乙肝病毒株的复制效率。
J Viral Hepat. 2013 Feb;20(2):141-8. doi: 10.1111/j.1365-2893.2012.01639.x. Epub 2012 Jul 3.

引用本文的文献

1
Resistance mutations of hepatitis B virus in entecavir-refractory patients.恩替卡韦耐药患者中乙型肝炎病毒的耐药突变
Hepatol Commun. 2017 Mar 9;1(2):110-121. doi: 10.1002/hep4.1022. eCollection 2017 Apr.
2
Tenofovir lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study.替诺福韦酯拉米夫定加阿德福韦酯治疗慢性乙型肝炎：TENOSIMP-B 研究。
World J Gastroenterol. 2017 Nov 7;23(41):7459-7469. doi: 10.3748/wjg.v23.i41.7459.
3
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.替诺福韦在拉米夫定治疗失败患者中的疗效与核苷（酸）类似物初治慢性乙型肝炎患者无差异。
Antimicrob Agents Chemother. 2013 Apr;57(4):1790-6. doi: 10.1128/AAC.02600-12. Epub 2013 Feb 4.
4
2-[(4-Chloro-benz-yl)sulfanyl]-4-(2-methyl-prop-yl)-6-[3-(trifluoro-meth-yl)anilino]-pyrimidine-5-carbonitrile.2-[(4-氯-苄基)硫烷基]-4-(2-甲基-丙基)-6-[3-(三氟-甲基)苯胺基]-嘧啶-5-腈
Acta Crystallogr Sect E Struct Rep Online. 2012 Jul 1;68(Pt 7):o2059-60. doi: 10.1107/S1600536812025895. Epub 2012 Jun 13.
5
2-[(4-Chloro-benz-yl)sulfan-yl]-4-(2-methyl-prop-yl)-6-(phenyl-sulfan-yl)pyrimidine-5-carbonitrile.2-[(4-氯-苄基)硫烷基]-4-(2-甲基-丙基)-6-(苯基硫烷基)嘧啶-5-腈
Acta Crystallogr Sect E Struct Rep Online. 2012 Jul 1;68(Pt 7):o2055-6. doi: 10.1107/S1600536812025810. Epub 2012 Jun 13.
6
6-(2-Methyl-prop-yl)-4-oxo-2-sulfanyl-idene-1,2,3,4-tetra-hydro-pyrimidine-5-carbonitrile.6-(2-甲基丙基)-4-氧代-2-硫亚基-1,2,3,4-四氢嘧啶-5-腈
Acta Crystallogr Sect E Struct Rep Online. 2012 Mar 1;68(Pt 3):o676-7. doi: 10.1107/S1600536812005119. Epub 2012 Feb 10.
7
In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.盐酸金雀花碱对临床野生型和拉米夫定耐药乙型肝炎病毒分离株的体外活性。
Eur J Pharmacol. 2012 May 15;683(1-3):10-5. doi: 10.1016/j.ejphar.2012.02.030. Epub 2012 Feb 24.
8
New approaches in the management of chronic hepatitis B: role of tenofovir.慢性乙型肝炎管理的新方法：替诺福韦的作用。
Infect Drug Resist. 2009;2:13-26. doi: 10.2147/idr.s3918. Epub 2009 Apr 24.
9
HBV life cycle and novel drug targets.HBV 生命周期和新型药物靶点。
Hepatol Int. 2011 Jun;5(2):644-53. doi: 10.1007/s12072-011-9261-3. Epub 2011 Mar 8.
10
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.慢性乙型肝炎病毒感染核苷（酸）类似物经治中国患者中乙型肝炎病毒的基因型耐药谱分析。
J Viral Hepat. 2011 Apr;18(4):e29-39. doi: 10.1111/j.1365-2893.2010.01360.x. Epub 2010 Sep 6.

本文引用的文献

1
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.慢性乙型肝炎病毒感染患者中恩替卡韦耐药性产生的逐步过程。
J Hepatol. 2007 Mar;46(3):531-8. doi: 10.1016/j.jhep.2006.11.016. Epub 2006 Dec 18.
2
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.一名肝移植患者中多重耐药乙型肝炎病毒株的选择。
Gastroenterology. 2006 Oct;131(4):1253-61. doi: 10.1053/j.gastro.2006.08.013. Epub 2006 Aug 16.
3
Evolution of multi-drug resistant hepatitis B virus during sequential therapy.序贯治疗期间多重耐药乙型肝炎病毒的演变
Hepatology. 2006 Sep;44(3):703-12. doi: 10.1002/hep.21290.
4
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.替诺福韦用于拉米夫定耐药的乙型肝炎病毒（HBV）感染患者且在阿德福韦治疗期间HBV DNA水平较高者。
Hepatology. 2006 Aug;44(2):318-25. doi: 10.1002/hep.21253.
5
Tenofovir disoproxil fumarate: role in hepatitis B treatment.替诺福韦酯富马酸盐：在乙型肝炎治疗中的作用。
Hepatology. 2006 Aug;44(2):309-13. doi: 10.1002/hep.21307.
6
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.替诺福韦对乙型肝炎病毒的细胞内代谢及体外活性
Antimicrob Agents Chemother. 2006 Jul;50(7):2471-7. doi: 10.1128/AAC.00138-06.
7
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.恩替卡韦治疗拉米夫定耐药的HBeAg阳性慢性乙型肝炎
Gastroenterology. 2006 Jun;130(7):2039-49. doi: 10.1053/j.gastro.2006.04.007.
8
Antiviral therapy of chronic hepatitis B.慢性乙型肝炎的抗病毒治疗
Antiviral Res. 2006 Sep;71(2-3):206-15. doi: 10.1016/j.antiviral.2006.04.003. Epub 2006 Apr 25.
9
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.一项关于接受拉米夫定治疗的慢性乙型肝炎患者拉米夫定耐药突变演变的前瞻性研究。
J Viral Hepat. 2006 Apr;13(4):278-88. doi: 10.1111/j.1365-2893.2005.00712.x.
10
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.2',3'-二脱氧-3'-氟鸟苷抗乙型肝炎病毒活性及交叉耐药谱的体外特性研究
Antimicrob Agents Chemother. 2006 Mar;50(3):955-61. doi: 10.1128/AAC.50.3.955-961.2006.

2,4-二氨基-6-[2-(膦酰甲氧基)乙氧基]嘧啶对多药耐药乙型肝炎病毒突变体的体外活性

In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.

作者信息

Brunelle M N, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F

机构信息

INSERM, U871, 151 Cours Albert Thomas, 69424 Lyon cedex 03, France.

出版信息

Antimicrob Agents Chemother. 2007 Jun;51(6):2240-3. doi: 10.1128/AAC.01440-06. Epub 2007 Mar 19.

DOI:10.1128/AAC.01440-06
PMID:17371827
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1891401/
Abstract

The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.

摘要

在体外评估了耐药乙型肝炎病毒（HBV）突变体对拉米夫定、阿德福韦、替诺福韦、恩替卡韦以及一种新型无环嘧啶类似物2,4-二氨基-6-[2-(膦酰甲氧基)乙氧基]-嘧啶（PMEO-DAPym）的敏感性。大多数耐药突变体，包括多重耐药菌株，对替诺福韦和PMEO-DAPym仍敏感。因此，后一种分子值得进一步评估用于治疗HBV感染。